It is important that future studies validate our results with different cohorts of HCC patients with different clinical pathological features and from different regions, in order to ultimately determine the usefulness of RYBP as a biomarker and a potential therapeutic target for HCC worldwide. This evidence concerns the gene RYBP and hepatocellular carcinoma.